Apogee Therapeutics Provides Pipeline Progress and Reports …
1 day ago · Virtual R&D Day to be held December 2, 2024 at 10am ET. SAN FRANCISCO and WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage ...
Apogee Therapeutics Launches with $169 Million to Develop …
SAN FRANCISCO, Dec. 7, 2022 /PRNewswire/ -- Apogee Therapeutics, LLC, a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people...
Apogee Therapeutics Highlights Pipeline Progress and Financials
1 day ago · Apogee Therapeutics, Inc. ( ) has released its Q3 earnings.Here is a breakdown of the information Apogee Therapeutics, Inc. presented to its investors. Apogee Therapeutics, Inc. is a clinical ...
Apogee Therapeutics Highlights Pipeline Progress and Reports …
May 13, 2024 · Nominated development candidate for APG990, a subcutaneous half-life extended monoclonal antibody targeting OX40L, with a Phase 1 trial in healthy volunteers expected to initiate in 2H 2024. $816 million cash, cash equivalents and …
Apogee Therapeutics Launches with $169 Million to Develop …
SAN FRANCISCO, Dec. 7, 2022 /PRNewswire/ -- Apogee Therapeutics, LLC, a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders, today announced the closing of a $149 million Series B financing.
Apogee Therapeutics Provides Pipeline Progress and Reports …
Aug 12, 2024 · Apogee plans combination studies of 777 + 990 (IL-13 and OX40L) and 777 + 333 (IL-13 and TSLP), with the potential for greater efficacy across I&I diseases, starting with the first clinical trial...
Apogee Therapeutics Highlights Pipeline Progress and Reports …
May 13, 2024 · Pipeline and Corporate Highlights and Upcoming Milestones. Initiated Phase 2 APG777 clinical trial: APG777 is a novel, subcutaneous (SQ) half-life extended monoclonal antibody (mAb) targeting IL ...
Apogee Therapeutics Announces First Participants Dosed in
Aug 19, 2024 · The APG990 Phase 1 clinical trial is designed as a double-blind, placebo-controlled, first-in-human, single-ascending dose trial in healthy volunteers. The study will evaluate the safety ...
Apogee Therapeutics Provides Pipeline Progress and Reports
Aug 12, 2024 · Pipeline and Corporate Highlights and Upcoming Milestones. First patient dosed in APG777 Phase 2 trial and on track for Part A data in 2H 2025: APG777 is a novel, subcutaneous (SQ) extended...
Michael Thomas Henderson Sells 15,000 Shares of Apogee Therapeutics ...
4 days ago · News From Our Partners. Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) CEO Michael Thomas Henderson sold 15,000 shares of the business's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $59.22, for a total transaction of $888,300.00.
- Some results have been removed